The scientist in charge said the effort would hopefully narrow down vaccine candidates to one by the end of the year.
The push to fast-track a vaccine is condensing at least “10 years of vaccine development and testing into a matter of months,” Reuters said.
The scientist said vaccine makers have “agreed to share data and lend the use of their clinical trial networks to competitors should their own candidate fail.”
Each vaccine that demonstrates promising preliminary data will be tested among 20,000 to 30,000 subjects starting in July.
Dr. Larry Corey, a vaccine expert at Fred Hutchinson Cancer Center in Seattle, who is organizing the effort, said between 100,000 to 150,00 people could be enrolled in the studies.
“If you don’t see a safety problem, you just keep going,” Dr. Francis Collins, director of the National Institutes of Health, told Reuters.
The effort to fast-track a vaccine is part of the public-private partnership called Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) announced last month.
After the news hit, E-Mini S&P500 moved up about 30bps — well-placed headline.
Just another vaccine pump headline?